StockData
ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc (ANIP) stock

ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$71.47+1.48 (+2.11%)

Close on Nov 18, 2026Market cap $1.64BP/E 15.2Yield –

ANI Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ANI Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $150.36M, up 889.9% year over year. For fiscal 2025 it was $111.09M, up 18922.8% from the year before. Over ten years it grew 13.0% a year on average. The highest annual figure on record is $111.09M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$111.09M+18922.8%
FY2024Dec 31, 2024$584.00K-98.8%
FY2023Dec 31, 2023$46.97M–
FY2022Dec 31, 2022-$35.28M–
FY2021Dec 31, 2021-$39.79M–
FY2020Dec 31, 2020-$16.02M-198.0%
FY2019Dec 31, 2019$16.35M-53.8%
FY2018Dec 31, 2018$35.36M+24.8%
FY2017Dec 31, 2017$28.33M+41.1%
FY2016Dec 31, 2016$20.08M-38.6%
FY2015Dec 31, 2015$32.70M+63.5%
FY2014Dec 31, 2014$20.01M+2127.8%
FY2013Dec 31, 2013$898.00K–
FY2012Dec 31, 2012-$42.00K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$40.46M+191.2%
Q1 FY2026Mar 31, 2026$38.89M+48.5%
Q4 FY2025Dec 31, 2025$34.77M–
Q3 FY2025Sep 30, 2025$36.24M–
Q2 FY2025Jun 30, 2025$13.89M+168.8%
Q1 FY2025Mar 31, 2025$26.19M+29.0%
Q4 FY2024Dec 31, 2024-$4.38M-165.1%
Q3 FY2024Sep 30, 2024-$20.52M-214.3%
Q2 FY2024Jun 30, 2024$5.17M-58.3%
Q1 FY2024Mar 31, 2024$20.31M+105.3%
Q4 FY2023Dec 31, 2023$6.73M+269.6%
Q3 FY2023Sep 30, 2023$17.95M–
Q2 FY2023Jun 30, 2023$12.40M–
Q1 FY2023Mar 31, 2023$9.90M–
Q4 FY2022Dec 31, 2022$1.82M–
Q3 FY2022Sep 30, 2022-$5.00M–
Q2 FY2022Jun 30, 2022-$12.91M–
Q1 FY2022Mar 31, 2022-$19.20M-730.4%
Q4 FY2021Dec 31, 2021-$23.72M-7267.1%
Q3 FY2021Sep 30, 2021-$3.56M-227.1%
Q2 FY2021Jun 30, 2021-$15.55M–
Q1 FY2021Mar 31, 2021$3.05M–
Q4 FY2020Dec 31, 2020$331.00K–
Q3 FY2020Sep 30, 2020$2.80M-61.8%
Q2 FY2020Jun 30, 2020-$11.31M-221.7%
Q1 FY2020Mar 31, 2020-$7.84M-278.1%
Q4 FY2019Dec 31, 2019-$4.67M-140.8%
Q3 FY2019Sep 30, 2019$7.33M-27.5%
Q2 FY2019Jun 30, 2019$9.29M+27.9%
Q1 FY2019Mar 31, 2019$4.40M-32.7%
Q4 FY2018Dec 31, 2018$11.45M+55.1%
Q3 FY2018Sep 30, 2018$10.11M+8.4%
Q2 FY2018Jun 30, 2018$7.26M+3.8%
Q1 FY2018Mar 31, 2018$6.54M+41.3%
Q4 FY2017Dec 31, 2017$7.38M+468.5%
Q3 FY2017Sep 30, 2017$9.33M+17.8%
Q2 FY2017Jun 30, 2017$6.99M–
Q1 FY2017Mar 31, 2017$4.63M–
Q4 FY2016Dec 31, 2016$1.30M–
Q3 FY2016Sep 30, 2016$7.92M–

More ANI Pharmaceuticals figures

See a number that looks wrong?